Entering License and Distribution Agreement of Edaravone in Viet Nam
On December 18, 2020, Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Vietnam Co., Ltd. have entered a license agreement to register and launch Radicava®/ Radicut® (edaravone) in Viet Nam.
Edaravone is an intravenous medication to treat amyotrophic lateral sclerosis (ALS).
ALS is a rare neurological disease that primarily affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements such as chewing, walking, breathing and talking. The nerves lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis. The disease is progressive, meaning the symptoms get worse over time.
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Vietnam Co., Ltd. are striving to contribute to the enrichment of quality of life in Vietnamese people.